Advanced search
Publication Cover
OncoImmunology Volume 2, 2013 - Issue 4
Submit an article Journal homepage
725
Views
32
CrossRef citations to date
0
Altmetric
Author's View

Interferon α may be back on track to treat acute myeloid leukemia

Evelien L.J.M. Smits Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, BelgiumCorrespondence[email protected]
,
Sébastien Anguille Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium
&
Zwi N. Berneman Tumor Immunology Group, Laboratory of Experimental Hematology, Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Antwerp, Belgium
Article: e23619 | Received 08 Jan 2013, Accepted 14 Jan 2013, Published online: 01 Apr 2013

Figures & data

Figure 1. Biological rationale behind the use of interferon α to treat acute myeloid leukemia. Interferon α (IFNα) can exert direct as well as indirect anticancer effects against acute myeloid leukemia (AML) cells. Indirect antineoplastic effects stem as IFNα stimulates dendritic cells (DCs), natural killer (NK) cells and T cells to exert antileukemic functions. By using pegylated (peg)-IFNα, sustained high serum levels of IFNα can be achieved, which is probably a prerequisite for the success of such an immunotherapeutic regimen against AML.

Figure 1. Biological rationale behind the use of interferon α to treat acute myeloid leukemia. Interferon α (IFNα) can exert direct as well as indirect anticancer effects against acute myeloid leukemia (AML) cells. Indirect antineoplastic effects stem as IFNα stimulates dendritic cells (DCs), natural killer (NK) cells and T cells to exert antileukemic functions. By using pegylated (peg)-IFNα, sustained high serum levels of IFNα can be achieved, which is probably a prerequisite for the success of such an immunotherapeutic regimen against AML.

Related Research Data

Maintenance therapy in AML: The past, the present and the future.
Source: Wiley
Type I interferons in anticancer immunity
Source: Springer Science and Business Media LLC
Peptide vaccines in cancer therapy
Source: Informa UK Limited
Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
Source: Springer Science and Business Media LLC
IFN-alpha skews monocytes into CD56+-expressing dendritic cells with potent functional activities in vitro and in vivo.
Source: The American Association of Immunologists
Immunotherapy in AML
Source: Wiley

Linking provided by 

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.